WO2002020614A3 - Endoglin spezifisches polypeptid, seine herstellung und verwendung - Google Patents

Endoglin spezifisches polypeptid, seine herstellung und verwendung Download PDF

Info

Publication number
WO2002020614A3
WO2002020614A3 PCT/EP2001/010197 EP0110197W WO0220614A3 WO 2002020614 A3 WO2002020614 A3 WO 2002020614A3 EP 0110197 W EP0110197 W EP 0110197W WO 0220614 A3 WO0220614 A3 WO 0220614A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
endoglin
specific polypeptide
polypeptide
protein
Prior art date
Application number
PCT/EP2001/010197
Other languages
English (en)
French (fr)
Other versions
WO2002020614A2 (de
Inventor
Roland Kontermann
Daniel Miller
Rolf Mueller
Original Assignee
Vectron Therapeutics Ag
Roland Kontermann
Daniel Miller
Rolf Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectron Therapeutics Ag, Roland Kontermann, Daniel Miller, Rolf Mueller filed Critical Vectron Therapeutics Ag
Priority to EP01980336A priority Critical patent/EP1315760A2/de
Priority to US10/363,349 priority patent/US20040053329A1/en
Priority to JP2002525233A priority patent/JP2004508035A/ja
Priority to CA002421202A priority patent/CA2421202A1/en
Publication of WO2002020614A2 publication Critical patent/WO2002020614A2/de
Publication of WO2002020614A3 publication Critical patent/WO2002020614A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Polypeptide, das spezifisch an die extrazelluläre Domäne des humanen Endoglin (CD105) Proteins bindet, sowie seine Herstellung und Verwendung.
PCT/EP2001/010197 2000-09-04 2001-09-04 Endoglin spezifisches polypeptid, seine herstellung und verwendung WO2002020614A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01980336A EP1315760A2 (de) 2000-09-04 2001-09-04 Endoglin spezifisches polypeptid, seine herstellung und verwendung
US10/363,349 US20040053329A1 (en) 2000-09-04 2001-09-04 Endoglin-specific polypeptide, production and use thereof
JP2002525233A JP2004508035A (ja) 2000-09-04 2001-09-04 エンドグリン特異的ポリペプチド、その製造及び使用
CA002421202A CA2421202A1 (en) 2000-09-04 2001-09-04 Endoglin-specific polypeptide, production and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043481A DE10043481A1 (de) 2000-09-04 2000-09-04 Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
DE10043481.9 2000-09-04

Publications (2)

Publication Number Publication Date
WO2002020614A2 WO2002020614A2 (de) 2002-03-14
WO2002020614A3 true WO2002020614A3 (de) 2002-08-01

Family

ID=7654886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010197 WO2002020614A2 (de) 2000-09-04 2001-09-04 Endoglin spezifisches polypeptid, seine herstellung und verwendung

Country Status (6)

Country Link
US (1) US20040053329A1 (de)
EP (1) EP1315760A2 (de)
JP (1) JP2004508035A (de)
CA (1) CA2421202A1 (de)
DE (1) DE10043481A1 (de)
WO (1) WO2002020614A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063735A1 (en) * 2004-12-14 2006-06-22 F. Hoffmann-La Roche Ag Endoglin as target/marker for insulin resistance
RU2559532C2 (ru) 2006-11-02 2015-08-10 Акселерон Фарма, Инк. Антагонисты рецептора и лигандов alk1 и их применение
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
EP3398966A1 (de) 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Verfahren und zusammensetzungen zur modulation von angiogenese und pericytzusammensetzung
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816141A1 (de) * 1998-04-09 1999-10-14 Hoechst Marion Roussel De Gmbh Einzelkettiges, mehrfach-antigenbindendes Molekül, dessen Herstellung und Verwendung
EP0952218A2 (de) * 1998-04-09 1999-10-27 Hoechst Marion Roussel Deutschland GmbH Einzelkettiges, mehrfach-antigenbindendes Moleküll, dessen Herstellung und Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE214075T1 (de) * 1996-05-31 2002-03-15 Health Research Inc Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816141A1 (de) * 1998-04-09 1999-10-14 Hoechst Marion Roussel De Gmbh Einzelkettiges, mehrfach-antigenbindendes Molekül, dessen Herstellung und Verwendung
EP0952218A2 (de) * 1998-04-09 1999-10-27 Hoechst Marion Roussel Deutschland GmbH Einzelkettiges, mehrfach-antigenbindendes Moleküll, dessen Herstellung und Verwendung

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GOUGOS A. ET AL.: "Identificiation of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts", INTERNATIONAL IMMUNOLOGY, vol. 4, no. 1, January 1992 (1992-01-01), pages 83 - 92, XP000886023 *
HAISMA HIDDE J ET AL: "Targeting of adenoviral vectors through a bispecific single-chain antibody.", CANCER GENE THERAPY, vol. 7, no. 6, June 2000 (2000-06-01), pages 901 - 904, XP001064497, ISSN: 0929-1903 *
HARA H. ET AL.: "Induction of Complete Regression of Distinct Tumors of Human Non-T Leukemia Cells in Nude Mice by Ricin A-Chain Conjugates of Monoclonal Antibodies SN5 and SN6", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 29, 1988, pages 420 - no. 1672, XP000886052 *
NETTELBECK D M ET AL: "Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin ( CD105 ).", MOLECULAR THERAPY, (2001 JUN) 3 (6) 882-91., XP001064461 *
PICHUANTES S ET AL: "Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments.", TISSUE ANTIGENS, vol. 50, no. 3, 1997, pages 265 - 276, XP001064499, ISSN: 0001-2815 *
SEON B. K. ET AL.: "Epitope mapping of endoglin, a TGF-beta receptor, by use of twelve SN6 series monoclonal antibodies", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 37, April 1996 (1996-04-01), pages 37 - no. 408, XP002137240 *

Also Published As

Publication number Publication date
US20040053329A1 (en) 2004-03-18
JP2004508035A (ja) 2004-03-18
DE10043481A1 (de) 2002-04-11
CA2421202A1 (en) 2003-03-04
WO2002020614A2 (de) 2002-03-14
EP1315760A2 (de) 2003-06-04

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU2002365258A1 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2002032383A3 (de) Neue verwendung von kurzkettigen carbonsäuren
WO2003057134A3 (en) Specific binding agents of human angiopoietin-2
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU4622297A (en) Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr)
AU2002232819A1 (en) Methods for the production of multimeric proteins, and related compositions
DE60128701D1 (en) Claudin polypeptide
WO2002079474A3 (en) Human b7 polypeptides
WO2001012660A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
HK1055750A1 (en) Monoclonal antibodies to the human ldl receptor, their production and use
WO2002100895A3 (de) Antimikrobiell wirkendes peptid
WO2002020614A3 (de) Endoglin spezifisches polypeptid, seine herstellung und verwendung
WO2001002563A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
WO2005010165A3 (en) Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
WO2003057712A3 (en) Humanized lactoferrin and uses thereof
ZA200403860B (en) Application of waistbands to garments.
WO2003074656A3 (en) Rank-ligand-induced sodium/proton antiporter polypeptides
WO2005011728A3 (en) Use of soluble cd164 in inflammatory and/or autoimmune disorders
WO2002032884A3 (en) Methods for the preparation of biphenyl isoxazole sulfonamides
WO2001004297A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
WO2002062915A8 (en) Paper products containing triboluminescent materials
WO2001083550A3 (en) Gpr22 modulators as appetite-control agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2002525233

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001980336

Country of ref document: EP

Ref document number: 2421202

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001980336

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10363349

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001980336

Country of ref document: EP